BlackRock
KLRS

BlackRock’s Kalaris Therapeutics KLRS Stock Holding History

BlackRock’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$208K Sell
36,043
-2,411
-6% -$21.4K ﹤0.01% 4756
2025
Q4 		$325K Sell
38,454
-1,925
-5% -$12.3K ﹤0.01% 4601
2025
Q3 		$233K Buy
40,379
+2,223
+6% +$7.35K ﹤0.01% 4648
2025
Q2 		$102K Buy
38,156
+10,642
+39% +$48K ﹤0.01% 4835
2025
Q1 		$221K Sell
27,514
-3
-0% -$29 ﹤0.01% 4582
2024
Q4 		$266K Hold
27,517
– – ﹤0.01% 4565
2024
Q3 		$512K Sell
27,517
-49
-0.2% -$857 ﹤0.01% 4318
2024
Q2 		$459K Sell
27,566
-119,644
-81% -$2.11M ﹤0.01% 4368
2024
Q1 		$2.56M Sell
147,210
-6,099
-4% -$99.5K ﹤0.01% 3913
2023
Q4 		$2.4M Sell
153,309
-13,892
-8% -$548K ﹤0.01% 3970
2023
Q3 		$8.27M Buy
167,201
+22,664
+16% +$1.54M ﹤0.01% 3446
2023
Q2 		$11.3M Buy
144,537
+28,299
+24% +$2.69M ﹤0.01% 3364
2023
Q1 		$10.5M Sell
116,238
-6,231
-5% -$794K ﹤0.01% 3293
2022
Q4 		$14.5M Buy
122,469
+6,492
+6% +$1.1M ﹤0.01% 3200
2022
Q3 		$21M Buy
115,977
+8,212
+8% +$1.28M ﹤0.01% 3005
2022
Q2 		$9.67M Buy
107,765
+10,769
+11% +$1.13M ﹤0.01% 3521
2022
Q1 		$15.1M Buy
96,996
+2,728
+3% +$544K ﹤0.01% 3351
2021
Q4 		$28.1M Buy
94,268
+15,434
+20% +$7.16M ﹤0.01% 3058
2021
Q3 		$45.4M Buy
78,834
+2,856
+4% +$1.32M ﹤0.01% 2723
2021
Q2 		$34.5M Sell
75,978
-27,199
-26% -$14M ﹤0.01% 2945
2021
Q1 		$55.5M Buy
103,177
+24,284
+31% +$20.4M ﹤0.01% 2547
2020
Q4 		$69.8M Buy
78,893
+27,955
+55% +$21.5M ﹤0.01% 2276
2020
Q3 		$32.2M Buy
+50,938
New +$34.8M ﹤0.01% 2562

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

BlackRock's KLRS Position: Q1 2026 in Review

BlackRock reduced its Kalaris Therapeutics (KLRS) stake by 6.3% in Q1 2026, selling an estimated $21.4K and leaving 36,043 shares worth $208K. The position accounts for ﹤0.01% of the portfolio, ranked #4756.

BlackRock first reported a position in KLRS in Q3 2020 and has held it in 23 quarters since. The position peaked at $69.8M in Q4 2020. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • BlackRock held 36,043 shares of Kalaris Therapeutics worth $208K as of Q1 2026.
  • BlackRock sold 2,411 Kalaris Therapeutics shares in Q1 2026, an estimated $21.4K.
  • Kalaris Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4756 holding.
  • BlackRock first reported a position in Kalaris Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • BlackRock's Kalaris Therapeutics position peaked at $69.8M in Q4 2020.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.